Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score‐matched cohort study

• Published in: Ai zheng 2016-05, Vol.35 (1), p.1-4, Article 45
• Main Authors: Chang, Yen‐Hou, Lu, Chien‐Hsing, Yen, Ming‐Shyen, Lee, Wai‐Hou, Chang, Yi, Chang, Wei‐Pin, Chuang, Chi‐Mu
• Format: Article
• Language: English
• Subjects: Analysis; Antimitotic agents; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer; Carcinoma, Ovarian Epithelial; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - therapeutic use; Clinical trials; Cytoreduction Surgical Procedures; Drug Administration Schedule; Epithelial ovarian, tubal, and peritoneal cancer; Fallopian Tube Neoplasms - drug therapy; Fallopian Tube Neoplasms - surgery; Female; Humans; Injections, Intraperitoneal; Intraperitoneal chemotherapy; Letter to the Editor; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - surgery; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - surgery; Paclitaxel - administration & dosage; Paclitaxel - therapeutic use; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - surgery; Propensity Score; Prospective Studies; Survival; Treatment Outcome
• ISSN: 2523-3548; 1944-446X; 1000-467X; 2523-3548; 1944-446X
• DOI: 10.1186/s40880-016-0105-3

We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score‐matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3‐week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin‐based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose‐dense intraperitoneal delivery of paclitaxel or a dose‐dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.